ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma

Michael Lim, MD
Published Online:10:26 AM, Tue February 9, 2016

Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma. Lim says medical professionals should be aware of the toxicities that come along with these checkpoint inhibitors, as well as be able to recognize the first signs of toxicities.

Lim says the two most concerning toxicities stemming from the use of checkpoint inhibitors in glioblastoma are colitis, as well as an inflammitory reaction in a patient's colon or pneumonitis.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.